Aging cells may help explain melanoma resistance, but proposed treatments remain experimental
A review describes how aging processes in tumor and immune cells may contribute to melanoma treatment resistance. Approaches targeting these processes still need clinical safety and efficacy testing.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
The review describes how aging-related changes in melanoma cells, surrounding tissue, and immune cells may work together to weaken antitumor responses. Treatments aimed at these processes have shown promise in preclinical models. That provides a rationale for further research, without establishing that these treatments safely improve immunotherapy response or survival in people with melanoma.
The abstract provides a mechanistic synthesis without study counts, pooled effect estimates, or demonstrated patient benefits from targeting senescence. It explicitly states that clinical safety and efficacy require further investigation.
A proposed reinforcing cycle
Senescent tumor cells and nearby tissue cells release signals that can promote inflammation and suppress immune activity. At the same time, aging immune cells may become less effective, creating conditions that could undermine immune checkpoint treatments.
What experimental targeting means
The review discusses approaches aimed at senescent cells or the signals they release. Its treatment claims rest on preclinical promise, so the abstract does not identify a clinically validated strategy for overcoming melanoma resistance.
The original publication
Cellular Senescence and Immunosenescence in Melanoma: Insights From the Tumor Microenvironment.
Xiong L, Cheng J
Cancer Med · 2025
- PubMed ID
- 40926366
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.